4 ms·

The article was posted in September. Since then all analysis has validated the booster strategy, even in individuals who previously had COVID. The increase in i

The article was posted in September. Since then all analysis has validated the booster strategy, even in individuals who previously had COVID. The increase in incidence in pediatric COVID patients since the Omicron wave supports the assertion as well. I'm sorry but new meta-analyses are coming up every week. It's been 4 months since that article and the conclusions in said opinion piece have been proven wrong.

native_samples 5y ago
Could you explain where you're getting your information because, as timr points out in several different ways, it isn't true.
timr 5y ago
- dang 5y ago
  > No, it hasn't. You are making things up -- which is why you keep [etc.] Flamewar swipes have repeatedly been creeping back into your comments here. Please edit them out. Not only are they against the site guidelines, they discredit your position, which is particularly bad in the case that you happen to be correct. https://news.ycombinator.com/newsguidelines.html https://news.ycombinator.com/newsguidelines.html https://hn.algolia.com/?dateRange=all&page=0&prefix=true&sort=byDate&type=comment&query=truth%20discredit%20by:dang https://hn.algolia.com/?dateRange=all&page=0&prefix=true&sor...
timr 5y ago
> Since then all analysis has validated the booster strategy, even in individuals who previously had COVID. No, it hasn't. Just a week ago: https://vinayprasadmdmph.substack.com/p/vaccine-effectiveness-goes-down-the https://vinayprasadmdmph.substack.com/p/vaccine-effectivenes... Vaccine efficacy for 3rd dose, out of Ontario, is somewhere in the 30-40% range. In Denmark, secondary attack rate for 3 doses is essentially equivalent to being unvaccinated. This is the latest data we have. In the UK, December 28, 2021: > efficacy of a third dose of a COVID-19 vaccine waned significantly at the 10-week mark, leaving boosted individuals at risk of infection with Omicron....In a December 23 U.K. Health Security Agency (HSA) technical briefing, vaccine efficacy against symptomatic infection generally fell to around 40% some 2.5 months after a booster dose. https://www.medpagetoday.com/special-reports/exclusives/96412 https://www.medpagetoday.com/special-reports/exclusives/9641... Also from the UK (January 6, 2022): vaccine effectiveness against symptomatic infection, 2-4 weeks after dose 3, is essentially equivalent to effectiveness after dose 2: https://twitter.com/PaulMainwood/status/1481220965539500032 https://twitter.com/PaulMainwood/status/1481220965539500032 Denmark again, January 5, 2022: > data just released from Denmark (where 85% of infections are omicron) show no effect of the booster against being infected and no difference between 2 and 3 doses against severe disease except 3 doses better against severe disease for those >70. https://twitter.com/TracyBethHoeg/status/1478853178699354112 https://twitter.com/TracyBethHoeg/status/1478853178699354112 The overall picture is of a vaccine that is temporarily elevating antibody levels, which then decline rapidly. But this isn't unexpected. It's exactly what we thought would happen. Moderna CEO, January 6, 2022: > Bancel said the efficacy of boosters will probably decline over the course of several months, similar to what happened with the first two doses. https://www.cnbc.com/2022/01/06/moderna-ceo-says-people-may-need-fourth-covid-shot-as-efficacy-of-boosters-likely-to-decline-over-time.html https://www.cnbc.com/2022/01/06/moderna-ceo-says-people-may-... ...but don't worry! Because the good news is that we have really solid data that after only two doses, even high-risk people remain well-protected against severe disease: > Among 1,228,664 persons who completed primary vaccination during December 2020–October 2021, severe COVID-19–associated outcomes (0.015%) or death (0.0033%) were rare. Risk factors for severe outcomes included age ≥65 years, immunosuppressed, and six other underlying conditions. All persons with severe outcomes had at least one risk factor; 78% of persons who died had at least four. https://www.cdc.gov/mmwr/volumes/71/wr/mm7101a4.htm https://www.cdc.gov/mmwr/volumes/71/wr/mm7101a4.htm

native_samples 5y ago

Could you explain where you're getting your information because, as timr points out in several different ways, it isn't true.

timr 5y ago

dang 5y ago
> No, it hasn't. You are making things up -- which is why you keep [etc.] Flamewar swipes have repeatedly been creeping back into your comments here. Please edit them out. Not only are they against the site guidelines, they discredit your position, which is particularly bad in the case that you happen to be correct. https://news.ycombinator.com/newsguidelines.html https://news.ycombinator.com/newsguidelines.html https://hn.algolia.com/?dateRange=all&page=0&prefix=true&sort=byDate&type=comment&query=truth%20discredit%20by:dang https://hn.algolia.com/?dateRange=all&page=0&prefix=true&sor...

timr 5y ago

> Since then all analysis has validated the booster strategy, even in individuals who previously had COVID. No, it hasn't. Just a week ago: https://vinayprasadmdmph.substack.com/p/vaccine-effectiveness-goes-down-the https://vinayprasadmdmph.substack.com/p/vaccine-effectivenes... Vaccine efficacy for 3rd dose, out of Ontario, is somewhere in the 30-40% range. In Denmark, secondary attack rate for 3 doses is essentially equivalent to being unvaccinated. This is the latest data we have. In the UK, December 28, 2021: > efficacy of a third dose of a COVID-19 vaccine waned significantly at the 10-week mark, leaving boosted individuals at risk of infection with Omicron....In a December 23 U.K. Health Security Agency (HSA) technical briefing, vaccine efficacy against symptomatic infection generally fell to around 40% some 2.5 months after a booster dose. https://www.medpagetoday.com/special-reports/exclusives/96412 https://www.medpagetoday.com/special-reports/exclusives/9641... Also from the UK (January 6, 2022): vaccine effectiveness against symptomatic infection, 2-4 weeks after dose 3, is essentially equivalent to effectiveness after dose 2: https://twitter.com/PaulMainwood/status/1481220965539500032 https://twitter.com/PaulMainwood/status/1481220965539500032 Denmark again, January 5, 2022: > data just released from Denmark (where 85% of infections are omicron) show no effect of the booster against being infected and no difference between 2 and 3 doses against severe disease except 3 doses better against severe disease for those >70. https://twitter.com/TracyBethHoeg/status/1478853178699354112 https://twitter.com/TracyBethHoeg/status/1478853178699354112 The overall picture is of a vaccine that is temporarily elevating antibody levels, which then decline rapidly. But this isn't unexpected. It's exactly what we thought would happen. Moderna CEO, January 6, 2022: > Bancel said the efficacy of boosters will probably decline over the course of several months, similar to what happened with the first two doses. https://www.cnbc.com/2022/01/06/moderna-ceo-says-people-may-need-fourth-covid-shot-as-efficacy-of-boosters-likely-to-decline-over-time.html https://www.cnbc.com/2022/01/06/moderna-ceo-says-people-may-... ...but don't worry! Because the good news is that we have really solid data that after only two doses, even high-risk people remain well-protected against severe disease: > Among 1,228,664 persons who completed primary vaccination during December 2020–October 2021, severe COVID-19–associated outcomes (0.015%) or death (0.0033%) were rare. Risk factors for severe outcomes included age ≥65 years, immunosuppressed, and six other underlying conditions. All persons with severe outcomes had at least one risk factor; 78% of persons who died had at least four. https://www.cdc.gov/mmwr/volumes/71/wr/mm7101a4.htm https://www.cdc.gov/mmwr/volumes/71/wr/mm7101a4.htm